Literature DB >> 27310544

Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study - sample of São José do Rio Preto.

Gabriel Costa de Andrade1, Luciana Harumi Fujise2, Jaime Euclides de Santana2, Fabiane Oliveira3, Rita de Cássia Martins Alves da Silva4.   

Abstract

INTRODUCTION: NAFLD is an heterogeneous condition that includes steatosis and non-alcoholic steatohepatitis (NASH), in the absence of significant alcohol consumption, reaching 30% of the population. The most common risk factors are: age, gender, ethnicity, diabetes mellitus (DM), obesity, predisposition, metabolic syndrome (MS), insulin resistance (IR), drugs, and polycystic ovary syndrome.
OBJECTIVE: To describe the profile of patients with NAFLD seen at Hospital de Base of Rio Preto, in the state of São Paulo.
METHOD: Patients with NAFLD were assessed, with medical and epidemiological data collected after informed consent.
RESULTS: Of the 62 patients evaluated, 76% were women, 73% Caucasians, and 71% were aged between 50 and 69 years and had no symptoms. Ultrasonography results showed steatosis in 84%. NASH was diagnosed in 61% of the sample. 21 patients underwent liver biopsy, of which 36% had cirrhosis, 1 had liver cancer, and 1 pure steatosis (5% each). Risk factors were found in 70% of patients with metabolic syndrome, 87% with increased waist circumference, 63% with dyslipidemia, 61% (n=38) with high blood pressure (HBP), 28% with DM, 52% physically inactive, and 44% with insulin resistance (IR) (HOMA> 3.5). There was an association between IR and NASH (p=0.013), IR and obesity (p=0.027), IR and MS (p=0.006), and MS and steatosis on medical ultrasound (USG) (p=0.014).
CONCLUSION: The most frequent risk factors were MS and its variables: increased waist circumference, dyslipidemia and HBP. This underscores the importance of metabolic control in NAFLD and confirms its role as the hepatic component of metabolic syndrome.

Entities:  

Mesh:

Year:  2016        PMID: 27310544     DOI: 10.1590/1806-9282.62.03.218

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  2 in total

Review 1.  Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.

Authors:  Naga S Samji; Rajanshu Verma; Sanjaya K Satapathy
Journal:  J Clin Exp Hepatol       Date:  2019-05-16

2.  Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFNα-2a in Patients with Chronic Hepatitis B and the Associated Mechanism.

Authors:  Huiqing Liang; Yaoyu Liu; Xiaoqian Jiang; Xiaoting Zheng; Jinmo Tang; Jiaen Yang; Hongli Zhuang; Penghua Lai; Li Peng; Zhenying Guo; Shanshan Cai; Dan Luo; Lingxia Xu; Qianguo Mao; Shaodong Chen
Journal:  Gastroenterol Res Pract       Date:  2020-06-26       Impact factor: 2.260

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.